title: Moving East: the Euro-Lupus Nephritis regimen in Asia.
abstract: Treatment of lupus nephritis is more evidenced-based than ever. Yet many areas of uncertainty persist. The article by Rathi et al. brings a piece to the puzzle by comparing, in a group of Indian patients, the Euro-Lupus low-dose i.v. cyclophosphamide regimen with mycophenolate mofetil. Although some caveats must be raised, the results suggest that, after crossing the Atlantic, the Euro-Lupus regimen may well be moving East.
authors.affiliation: Rheumatology Department, Cliniques Universitaires Saint-Luc, Pôle de Pathologies Rhumatismales Inflammatoires et Systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium. Electronic address: frederic.houssiau@uclouvain.be.
authors.forename: Frédéric A
authors.initials: FA
authors.lastname: Houssiau
mesh_terms: D001208:Asia; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008181:Lupus Nephritis / Q000188:drug therapy*; D035501:Uncertainty
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide